[ad_1] Orally administered EB-373 resulted in dose-dependent increase in psilocin blood concentration in pharmacokinetic (PK) animal studies, correlating to levels expected to be effective based on psilocybin data in humans Outcome of animal studies indicate potential to reduce GI upset and vomiting as well as rapid onset of action and systemic clearance, improving on PK […]